Releases Details
Director/PDMR Shareholding
Released : July 26, 2018 17:33
MaxCyte, Inc.
("MaxCyte" or the "Company")
Person Closely Associated Dealing
Following this purchase, John Johnston has a beneficial interest of 86,500 Common Stock, representing 0.2% of the issued share capital of the Company and a further 64,800 options over Common Stock.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Karin Johnston |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Person closely associated |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MaxCyte, Inc. |
|
|
b) |
LEI |
54930053YHXULRFCU991 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Purchase of Common Stock |
|
|
b) |
Identification Code |
US57777K1060 |
|
|
c) |
Nature of the transaction |
Purchase of Common Stock by a person closely associated |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
11,500 |
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A (Single Transaction) 11,500 240.00 |
|
|
f) |
Date of the transaction |
26 July 2018 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market |
|
For further information, please contact:
|
MaxCyte Inc. |
|
|
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer |
+1 301 944 1660 |
|
Nominated Adviser and Broker Panmure Gordon |
|
|
Emma Earl, Freddy Crossley, Ryan McCarthy (Corporate Finance) James Stearns (Corporate Broking) |
+44 (0) 20 7886 2500
|
|
Financial PR Adviser Consilium Strategic Communications |
|
|
Mary-Jane Elliott Chris Welsh Sukaina Virji
|
+44 (0)203 709 5700 |
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered programme licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
